Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa

Journal of Clinical Virology

Volumn 61, Issue 1, 2014, Pages 20-33

  Matthews, Philippa C ^a,b   Geretti, Anna Maria ^c   Goulder, Philip J R ^a,b   Klenerman, Paul ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Africa; Coinfection; Epidemiology; Hepatitis B; Hepatitis C; HIV 1

Indexed keywords

ADEFOVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; STAVUDINE; TELBIVUDINE; TENOFOVIR;

AFRICA SOUTH OF THE SAHARA; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS (TOPIC); MIXED INFECTION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; REVIEW; SCREENING; SEROEPIDEMIOLOGY; COINFECTION; COMPLICATION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; VIROLOGY;

AFRICA SOUTH OF THE SAHARA; COINFECTION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 84905095021     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.05.018     Document Type: Review

References (160)

1. Bonacini M., Louie S., Bzowej N., Wohl A.R. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004, 18:2039-2045.
2. Ioannou G.N., Bryson C.L., Weiss N.S., Miller R., Scott J.D., Boyko E.J. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013, 57:249-257.
3. Kourtis A.P., Bulterys M., Hu D.J., Jamieson D.J. HIV-HBV coinfection - a global challenge. N Engl J Med 2012, 366:1749-1752.
4. Matthews G.V., Manzini P., Hu Z., Khabo P., Maja P., Matchaba G., et al. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 2011, 25:1727-1735.
5. Stabinski L., Reynolds S.J., Ocama P., Laeyendecker O., Ndyanabo A., Kiggundu V., et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther 2011, 16:405-411.
6. Ibrahim A., Shpaner A., Nieto J. Risk factors of accelerated liver fibrosis in HIV-HCV coinfection: a matched analysis. South Afr Gastroenterol Rev 2004, 2:14-17.
7. Mphahlele M.J. Impact of HIV co-infection on hepatitis B prevention and control: a view from Sub-Saharan Africa. South Afr J Epidemiol Infect 2008, 23.
8. Agwale S.M., Tanimoto L., Womack C., Odama L., Leung K., Duey D., et al. Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes. J Clin Virol 2004, 31(Suppl. 1):S3-S6.
9. Attia K.A., Eholie S., Messou E., Danel C., Polneau S., Chenal H., et al. Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients. World J Hepatol 2012, 4:218-223.
10. Adesina O., Oladokun A., Akinyemi O., Adedokun B., Awolude O., Odaibo G., et al. Human immuno-deficiency virus and hepatitis B virus coinfection in pregnancy at the University College Hospital, Ibadan. Afr J Med Med Sci 2010, 39:305-310.
11. Idoko J., Meloni S., Muazu M., Nimzing L., Badung B., Hawkins C., et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009, 49:1268-1273.
12. Adekunle A.E., Oladimeji A.A., Temi A.P., Adeseye A.I., Akinyeye O.A., Taiwo R.H. Baseline CD4+ T lymphocyte cell counts, hepatitis B and C viruses seropositivity in adults with human immunodeficiency virus infection at a tertiary hospital in Nigeria. Pan Afr Med J 2011, 9:6.
13. lsa S.E., Gwamzhi L.N., Akolo C., Giyan J. A prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria. Niger J Med 2010, 19:279-285.
14. Hoffmann C.J., Charalambous S., Martin D.J., Innes C., Churchyard G.J., Chaisson R.E., et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008, 47:1479-1485.
15. Di Bisceglie A.M., Maskew M., Schulze D., Reyneke A., McNamara L., Firnhaber C. HIV-HBV coinfection among South African patients receiving antiretroviral therapy. Antivir Ther 2010, 15:499-503.
16. Rouet F., Chaix M.L., Inwoley A., Anaky M.F., Fassinou P., Kpozehouen A., et al. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. Clin Infect Dis 2008, 46:361-366.
17. UNAIDS UNAIDS World AIDS Day Report: Fact Sheet 2011, http://wwwunaidsorg/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_FactSheet_Global_enpdf.
18. Geretti A.M., Patel M., Sarfo F.S., Chadwick D., Verheyen J., Fraune M., et al. Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol 2010, 48:3223-3230.
19. Eke A.C., Eke U.A., Okafor C.I., Ezebialu I.U., Ogbuagu C. Prevalence, correlates and pattern of hepatitis B surface antigen in a low resource setting. Virol J 2011, 8:12.
20. Gravitz L. Introduction: a smouldering public-health crisis. Nature 2011, 474:S2-S4.
21. Wiersma S.T., McMahon B., Pawlotsky J.M., Thio C.L., Thursz M., Lim S.G., et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011, 31:755-761.
22. Cunha L., Plouzeau C., Ingrand P., Gudo J.P., Ingrand I., Mondlane J., et al. Use of replacement blood donors to study the epidemiology of major blood-borne viruses in the general population of Maputo, Mozambique. J Med Virol 2007, 79:1832-1840.
23. Sagoe K.W., Agyei A.A., Ziga F., Lartey M., Adiku T.K., Seshi M., et al. Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naive patients with HIV infection at a major treatment center in Ghana. J Med Virol 2012, 84:6-10.
24. Ramos J.M., Toro C., Reyes F., Amor A., Gutierrez F. Seroprevalence of HIV-1, HBV, HTLV-1 and Treponema pallidum among pregnant women in a rural hospital in Southern Ethiopia. J Clin Virol 2011, 51:83-85.
25. Harania R.S., Karuru J., Nelson M., Stebbing J. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS 2008, 22:1221-1222.
26. Patel P., Davis S., Tolle M., Mabikwa V., Anabwani G. Prevalence of hepatitis B and hepatitis C coinfections in an adult HIV centre population in Gaborone, Botswana. Am J Trop Med Hyg. 2011, 85:390-394.
27. Amin J., Kaye M., Skidmore S., Pillay D., Cooper D.A., Dore G.J. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004, 5:174-179.
28. Chen J.J., Yu C.B., Du W.B., Li L.J. Prevalence of hepatitis B and C in HIV-infected patients: a meta-analysis. Hepatobiliary Pancreat Dis Int 2011, 10:122-127.
29. Guimaraes Nebenzahl H., Lopes A., Castro R., Pereira F. Prevalence of human immunodeficiency virus, hepatitis C virus, hepatitis B virus and syphilis among individuals attending anonymous testing for HIV in Luanda, Angola. South Afr Med J 2013, 103:186-188.
30. Noubiap J.J., Joko W.Y., Nansseu J.R., Tene U.G., Siaka C. Sero-epidemiology of human immunodeficiency virus, hepatitis B and C viruses, and syphilis infections among first-time blood donors in Edea, Cameroon. Int J Infect Dis 2013, 17:e832-e837.
31. Adoga M.P., Banwat E.B., Forbi J.C., Nimzing L., Pam C.R., Gyar S.D., et al. Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria. J Infect Dev Ctries 2009, 3:539-547.
32. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44:S6-S9.
33. Kaplan J.E., Benson C., Holmes K.H., Brooks J.T., Pau A., Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009, 58:1-207. quiz CE1-4.
34. Anigilaje E.A., Olutola A. Prevalence and Clinical and Immunoviralogical Profile of human immunodeficiency virus-Hepatitis B Coinfection among Children in an Antiretroviral Therapy Programme in Benue State, Nigeria. ISRN Pediatr 2013, 2013:932697.
35. de Oliveira T., Pybus O.G., Rambaut A., Salemi M., Cassol S., Ciccozzi M., et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature 2006, 444:836-837.
36. Antaki N., Craxi A., Kamal S., Moucari R., Van der Merwe S., Haffar S., et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2009, 30:342-355.
37. Umolu P.I., Okoror L.E., Orhue P. Human immunodeficiency virus (HIV) seropositivity and hepatitis B surface antigenemia (HBSAG) among blood donors in Benin city, Edo state, Nigeria. Afr Health Sci 2005, 5:55-58.
38. Laurent C., Bourgeois A., Mpoudi-Ngole E., Kouanfack C., Ciaffi L., Nkoue N., et al. High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy. HIV Med 2010, 11:85-89.
39. Kew M.C. Hepatocellular carcinoma in African Blacks: recent progress in etiology and pathogenesis. World J Hepatol 2010, 2:65-73.
40. Zeba M.T., Karou S.D., Sagna T., Djigma F., Bisseye C., Ouermi D., et al. HCV prevalence and co-infection with HIV among pregnant women in Saint Camille Medical Centre, Ouagadougou. Trop Med Int Health 2011, 16:1392-1396.
41. Hoffmann C.J., Thio C.L. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007, 7:402-409.
42. WHO Introduction of hepatitis B vaccine into childhood immunization services. WHO Department of Vaccines and Biologicals: Expanded Programme on Immunization 2001.
43. Polis C.B., Shah S.N., Johnson K.E., Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. Clin Infect Dis 2007, 44:1123-1131.
44. Sangare L., Sombie R., Combassere A.W., Kouanda A., Kania D., Zerbo O., et al. Antenatal transmission of hepatitis B virus in an area of HIV moderate prevalence, Burkina Faso. Bull Soc Pathol Exot 2009, 102:226-229.
45. Kapembwa K.C., Goldman J.D., Lakhi S., Banda Y., Bowa K., Vermund S.H., et al. HIV, Hepatitis B, and Hepatitis C in Zambia. J Glob Infect Dis 2011, 3:269-274.
46. Uneke C.J., Ogbu O., Inyama P.U., Anyanwu G.I., Njoku M.O., Idoko J.H. Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz 2005, 100:13-16.
47. Collenberg E., Ouedraogo T., Ganame J., Fickenscher H., Kynast-Wolf G., Becher H., et al. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: a comparative analysis. J Med Virol 2006, 78:683-692.
48. Barth R.E., Huijgen Q., Taljaard J., Hoepelman A.I. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010, 14:e1024-e1031.
49. Moges F., Kebede Y., Kassu A., Mulu A., Tiruneh M., Degu G., et al. Seroprevalence of HIV, hepatitis B infections and syphilis among street dwellers in Gondar city, Northwest Ethiopia. Ethiopian J Health Dev 2006, 20:160-169.
50. Mayaphi S.H., Roussow T.M., Masemola D.P., Olorunju S.A., Mphahlele M.J., Martin D.J. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. South Afr Med J 2012, 102:157-162.
51. Lukhwareni A., Burnett R.J., Selabe S.G., Mzileni M.O., Mphahlele M.J. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol 2009, 81:406-412.
52. Muro F.J., Fiorillo S.P., Sakasaka P., Odhiambo C., Reddy E.A., Cunningham C.K., et al. Seroprevalence of hepatitis B and C viruses among children in Kilimanjaro region, Tanzania. J Pediatric Infect Dis Soc 2013, 2:320-326.
53. Ilboudo D., Simpore J., Ouermi D., Bisseye C., Sagna T., Odolini S., et al. Towards the complete eradication of mother-to-child HIV/HBV coinfection at Saint Camille Medical Centre in Burkina Faso, Africa. Braz J Infect Dis 2010, 14:219-224.
54. Njouom R., Pasquier C., Ayouba A., Tejiokem M.C., Vessiere A., Mfoupouendoun J., et al. Low risk of mother-to-child transmission of hepatitis C virus in Yaounde, Cameroon: the ANRS 1262 study. Am J Trop Med Hyg 2005, 73:460-466.
55. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC) 2011, http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
56. Balogun T.M., Durojaiye I.O., Sagoe A., Emmanuel S. Seroepidemiology of hepatitis-B surface antigenaemia in HIV positive patients. West Afr J Med 2010, 29:169-173.
57. Diop-Ndiaye H., Toure-Kane C., Etard J.F., Lo G., Diaw P., Ngom-Gueye N.F., et al. Hepatitis B C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 2008, 80:1332-1336.
58. Jobarteh M., Malfroy M., Peterson I., Jeng A., Sarge-Njie R., Alabi A., et al. Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J 2010, 7:230.
59. Balogun T.M., Emmanuel S., Ojerinde E.F. HIV Hepatitis B and C viruses' coinfection among patients in a Nigerian tertiary hospital. Pan Afr Med J 2012, 12:100.
60. Otegbayo J.A., Taiwo B.O., Akingbola T.S., Odaibo G.N., Adedapo K.S., Penugonda S., et al. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Ann Hepatol 2008, 7:152-156.
61. Dziuban E.J., Marton S.A., Hughey A.B., Mbingo T.L., Draper H.R., Schutze G.E. Seroprevalence of hepatitis B in a cohort of HIV-infected children and adults in Swaziland. Int J STD AIDS 2013, 24:561-565.
62. Hamers R.L., Zaaijer H.L., Wallis C.L., Siwale M., Ive P., Botes M.E., et al. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr 2013, 64:174-182.
63. Hawkins C., Christian B., Ye J., Nagu T., Aris E., Chalamilla G., et al. Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS 2013, 27:919-927.
64. Burnett R.J., Kramvis A., Dochez C., Meheus A. An update after 16 years of hepatitis B vaccination in South Africa. Vaccine 2012, 30(Suppl. 3):C45-C51.
65. Agbaji O., Thio C.L., Meloni S., Graham C., Muazu M., Nimzing L., et al. Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2013, 62:204-207.
66. Langar H., Triki H., Gouider E., Bahri O., Djebbi A., Sadraoui A., et al. Blood-transmitted viral infections among haemophiliacs in Tunisia. Transfus Clin Biol 2005, 12:301-305.
67. Iles J.C., Abby Harrison G.L., Lyons S., Djoko C.F., Tamoufe U., Lebreton M., et al. Hepatitis C virus infections in the Democratic Republic of Congo exhibit a cohort effect. Infect Genet Evol 2013, 19:386-394.
68. Forbi J.C., Gabadi S., Alabi R., Iperepolu H.O., Pam C.R., Entonu P.E., et al. The role of triple infection with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV) type-1 on CD4+ lymphocyte levels in the highly HIV infected population of North-Central Nigeria. Mem Inst Oswaldo Cruz 2007, 102:535-537.
69. Tremeau-Bravard A., Ogbukagu I.C., Ticao C.J., Abubakar J.J. Seroprevalence of hepatitis B and C infection among the HIV-positive population in Abuja, Nigeria. Afr Health Sci 2012, 12:312-317.
70. Telatela S.P., Matee M.I., Munubhi E.K. Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania. BMC Public Health 2007, 7:338.
71. Nyirenda M., Beadsworth M.B., Stephany P., Hart C.A., Hart I.J., Munthali C., et al. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect 2008, 57:72-77.
72. Egah D.Z., Banwat E.B., Audu E.S., Iya D., Mandong B.M., Anele A.A., et al. Hepatitis B surface antigen, hepatitis C and HIV antibodies in a low-risk blood donor group, Nigeria. East Mediterr Health J. 2007, 13:961-966.
73. Nagu T.J., Bakari M., Matee M. Hepatitis A, B and C viral co-infections among HIV-infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health 2008, 8:416.
74. Ladep N.G., Agaba P.A., Agbaji O., Muazu A., Ugoagwu P., Imade G., et al. Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World J Gastroenterol 2013, 19:1602-1610.
75. Thio C.L., Smeaton L., Saulynas M., Hwang H., Saravan S., Kulkarni S., et al. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS 2013, 27:191-201.
76. Soriano V., Grint D., d'Arminio Monforte A., Horban A., Leen C., Poveda E., et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011, 25:1987-1992.
77. Andersson M.I., Maponga T.G., Ijaz S., Barnes J., Theron G.B., Meredith S.A., et al. The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. Vaccine 2013, 31:5579-5584.
78. Foupouapouognigni Y., Noah D.N., Sartre M.T., Njouom R. High prevalence and predominance of hepatitis delta virus genotype 1 infection in Cameroon. J Clin Microbiol 2011, 49:1162-1164.
79. Firnhaber C., Chen C.Y., Evans D., Maskew M., Schulz D., Reyneke A., et al. Prevalence of hepatitis B virus (HBV) co-infection in HBV serologically-negative South African HIV patients and retrospective evaluation of the clinical course of mono- and co-infection. Int J Infect Dis 2012, 16:e268-e272.
80. Day S.L., Odem-Davis K., Mandaliya K.N., Jerome K.R., Cook L., Masese L.N., et al. Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy. PLoS ONE 2013, 8:e59346.
81. Kouanfack C., Aghokeng A.F., Mondain A.M., Bourgeois A., Kenfack A., Mpoudi-Ngole E., et al. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon. Antivir Ther 2012, 17:321-326.
82. Suzuki Y., Kobayashi M., Ikeda K., Suzuki F., Arfase Y., Akuta N., et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 2005, 76:33-39.
83. Garfein R.S., Bower W.A., Loney C.M., Hutin Y.J., Xia G.L., Jawanda J., et al. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004, 40:865-873.
84. Sheng W.H., Hung C.C., Chang S.Y., Liu C.J., Chen M.Y., Hsieh S.M., et al. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy. Clin Infect Dis 2012, 54:548-555.
85. Yoo T.W., Donfield S., Lail A., Lynn H.S., Daar E.S. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005, 191:4-10.
86. Mboto C.I., Fielder M., Davies-Russell A., Jewell A.P. Hepatitis C virus prevalence and serotypes associated with HIV in The Gambia. Br J Biomed Sci 2010, 67:140-144.
87. Rouet F., Chaix M.L., Inwoley A., Msellati P., Viho I., Combe P., et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 2004, 74:34-40.
88. Sheyin Z., Jatau B.D., Mamman A.I., Randawa A.J. Molecular epidemiology of hepatitis C virus (HCV) in Kadun State. Afr J Clin Exp Microbiol 2012, 13:61-65.
89. Hernandez M.D., Sherman K.E. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011, 6:478-482.
90. Nikolopoulos G.K., Paraskevis D., Hatzitheodorou E., Moschidis Z., Sypsa V., Zavitsanos X., et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009, 48:1763-1771.
91. Audsley J., du Cros P., Goodman Z., McLean C., Mijch A., Lewin S.R., et al. HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection. J Med Virol 2012, 84:993-1001.
92. Rodriguez-Torres M., Govindarajan S., Sola R., Clumeck N., Lissen E., Pessoa M., et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008, 48:756-764.
93. Darby S.C., Kan S.W., Spooner R.J., Giangrande P.L., Lee C.A., Makris M., et al. The impact of HIV on mortality rates in the complete UK haemophilia population. AIDS 2004, 18:525-533.
94. Ashir G.M., Rabasa A.I., Gofama M.M., Bukbuk D., Abubakar H., Farouk G.A. Study of hepatic functions and prevalence of hepatitis B surface antigenaemia in Nigerian children with human immunodeficiency virus infection. Niger J Med 2009, 18:260-262.
95. MacDonald D.C., Nelson M., Bower M., Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008, 14:1657-1663.
96. Ocama P., Opio K.C., Kagimu M., Seremba E., Wabinga H., Colebunders R. Hepatitis B virus and HIV infection among patients with primary hepatocellular carcinoma in Kampala, Uganda. Afr Health Sci 2011, 11(Suppl. 1):S20-S23.
97. Brook G., Main J., Nelson M., Bhagani S., Wilkins E., Leen C., et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010, 11:1-30.
98. N'Dri-Yoman T., Anglaret X., Messou E., Attia A., Polneau S., Toni T., et al. Occult HBV infection in untreated HIV-infected adults in Cote d'Ivoire. Antivir Ther 2010, 15:1029-1034.
99. Mohamed S., Raimondo A., Penaranda G., Camus C., Ouzan D., Ravet S., et al. Dried blood spot sampling for hepatitis B virus serology and molecular testing. PLoS ONE 2013, 8:e61077.
100. Kania D., Bekale A.M., Nagot N., Mondain A.M., Ottomani L., Meda N., et al. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa. Clin Microbiol Infect 2013, 19:E533-E541.
101. Barth R.E., Huijgen Q., Tempelman H.A., Mudrikova T., Wensing A.M., Hoepelman A.I. Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa. J Med Virol 2011, 83:929-934.
102. Firnhaber C., Viana R., Reyneke A., Schultze D., Malope B., Maskew M., et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 2009, 13:488-492.
103. Ayuk J., Mphahlele J., Bessong P. Hepatitis B virus in HIV-infected patients in northeastern South Africa: prevalence, exposure, protection and response to HAART. S Afr Med J 2013, 103:330-333.
104. Chasela C.S., Kourtis A.P., Wall P., Drobeniuc J., King C.C., Thai H., Hepatol F., et al. Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants. J Hepatol 2014, 60:508-514.
105. Bell T.G., Makondo E., Martinson N.A., Kramvis A. Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt - that is the question. PLoS ONE 2012, 7:e45750.
106. WHO Global Alert and Response: Hepatitis C 2003.
107. Pirillo M.F., Bassani L., Germinario E.A., Mancini M.G., Vyankandondera J., Okong P., et al. Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J Med Virol 2007, 79:1797-1801.
108. Mullis C.E., Laeyendecker O., Reynolds S.J., Ocama P., Quinn J., Boaz I., et al. High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda. Clin Infect Dis 2013, 57:1747-1750.
109. Dufour D.R., Talastas M., Fernandez M.D., Harris B., Strader D.B., Seeff L.B. Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. Clin Chem 2003, 49:479-486.
110. Yang J.F., Lin Y.Y., Hsieh M.H., Tsai C.H., Liu S.F., Yu M.L., et al. Performance characteristics of a combined hepatitis C virus core antigen and anti-hepatitis C virus antibody test in different patient groups. Kaohsiung J Med Sci 2011, 27:258-263.
111. Matthews G.V., Bartholomeusz A., Locarnini S., Ayres A., Sasaduesz J., Seaberg E., et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006, 20:863-870.
112. Soriano V., Puoti M., Peters M., Benhamou Y., Sulkowski M., Zoulim F., et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008, 22:1399-1410.
113. Feld J.J., Ocama P., Ronald A. The liver in HIV in Africa. Antivir Ther 2005, 10:953-965.
114. Mbougua J.B., Laurent C., Kouanfack C., Bourgeois A., Ciaffi L., Calmy A., et al. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health 2010, 10:105.
115. Chadwick D., Ankcorn M., Sarfo F., Phillips R., Fox Z., Garcia A., et al. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana. J Antimicrob Chemother 2012, 67:2939-2942.
116. Chadwick D., Stanley A., Sarfo S., Appiah L., Ankcorn M., Foster G., et al. Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa. AIDS 2013, 27:139-141.
117. Stewart B., Jobarteh M.L., Sarge-Njie R., Alabi A., de Silva T., Peterson K., et al. Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa. BMC Res Notes 2011, 4:561.
118. Ocama P., Katwere M., Piloya T., Feld J., Opio K.C., Kambugu A., et al. The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci 2008, 8:8-12.
119. EASL clinical practice guidelines Management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
120. Ramos B., Nunez M., Martin-Carbonero L., Sheldon J., Rios P., Labarga P., et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 2007, 44:557-561.
121. Price H., Dunn D., Pillay D., Bani-Sadr F., de Vries-Sluijs T., Jain M.K., et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS ONE 2013, 8:e68152.
122. Snow-Lampart A., Chappell B., Curtis M., Zhu Y., Myrick F., Schawalder J., et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011, 53:763-773.
123. Lacombe K., Bottero J., Lemoine M., Boyd A., Girard P.M. HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother 2010, 65:10-17.
124. Lacombe K., Boyd A., Lavocat F., Pichoud C., Gozlan J., Miailhes P., et al. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among HIV-hepatitis B infected patients. Hepatology 2013.
125. Soriano V., Tuma P., Vispo E., Labarga P., Fernandez J.V., Medrano J., et al. Hepatitis B in HIV patients: what is the current treatment and what are the challenges?. J HIV Ther 2009, 14:13-18.
126. Selabe S.G., Lukhwareni A., Song E., Leeuw Y.G., Burnett R.J., Mphahlele M.J. Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients. J Med Virol 2007, 79:1650-1654.
127. Bock C.T., Tillmann H.L., Torresi J., Klempnauer J., Locarnini S., Manns M.P., et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002, 122:264-273.
128. Sheldon J., Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008, 61:766-768.
129. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
130. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
131. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
132. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
133. Naggie S., Sulkowski M.S. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012, 142:e31324-e31334.
134. Magoni M., Ekra K.D., Aka L.N., Sita K.S., Kanga K. Effectiveness of hepatitis-B vaccination in Ivory Coast: the case of the Grand Bassam health district. Ann Trop Med Parasitol 2009, 103:519-527.
135. Immunisation Against Infectious Disease The Green Book 2012, The Stationery Office under licence from the Department of Health.
136. Simani O.E., Leroux-Roels G., Francois G., Burnett R.J., Meheus A., Mphahlele M.J. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine 2009, 27:146-151.
137. Pippi F., Bracciale L., Stolzuoli L., Giaccherini R., Montomoli E., Gentile C., et al. Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania. HIV Med 2008, 9:519-525.
138. del Pozo Balado Mdel M., Leal M., Mendez Lagares G., Mata R.C., Lopez-Cortes L.F., Viciana P., et al. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis 2010, 202:362-369.
139. Chu C.J., Lee S.D. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008, 23:512-520.
140. WHO Hepatitis C Fact Sheet Number 164 2012, http://wwwwhoint/mediacentre/factsheets/fs164/en/indexhtml.
141. WHO Hepatitis B Fact Sheet Number 204 2012, http://wwwwhoint/mediacentre/factsheets/fs204/en/.
142. Liu Z., Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 2006, 3:57-62.
143. Tounkara A., Sarro Y.S., Kristensen S., Dao S., Diallo H., Diarra B., et al. Seroprevalence of HIV/HBV coinfection in Malian blood donors. J Int Assoc Physicians AIDS Care (Chic) 2009, 8:47-51.
144. Nwolisa E., Mbanefo F., Ezeogu J., Amadi P. Prevalence of hepatitis B co-infection amongst HIV infected children attending a care and treatment centre in Owerri, South-eastern Nigeria. Pan Afr Med J 2013, 14:89.
145. Bwogi J., Braka F., Makumbi I., Mishra V., Bakamutumaho B., Nanyunja M., et al. Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci 2009, 9:98-108.
146. Funk A., Kanters S., Nansubuga M., Mwehire D., Featherstone A., Druyts E., et al. Cohort profile: the MUg Observational Cohort. Int J Epidemiol 2012, 41. pp. 1594-1594f.
147. Moore E., Beadsworth M.B., Chaponda M., Mhango B., Faragher B., Njala J., et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect 2010, 61:155-163.
148. Hoffmann C.J., Dayal D., Cheyip M., McIntyre J.A., Gray G.E., Conway S., et al. Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa. Int J STD AIDS 2012, 23:e10-e13.
149. Mavenyengwa R.T., Moyo S.R., Nordbo S.A. Streptococcus agalactiae colonization and correlation with HIV-1 and HBV seroprevalence in pregnant women from Zimbabwe. Eur J Obstet Gynecol Reprod Biol 2010, 150:34-38.
150. Hadush H., Gebre-Selassie S., Mihret A. Hepatitis C virus and human immunodeficiency virus coinfection among attendants of voluntary counseling and testing centre and HIV follow up clinics in Mekelle Hospital. Pan Afr Med J 2013, 14:107.
151. Waddell R.D., Magesa P.M., Pallangyo K.J., Matee M., Bakari M., von Reyn F., et al. Coinfection with HIV and HCV in a blood bank population in Dar es Salaam, Tanzania. J Clin Virol 2006, 36:237-238.
152. England K., Thorne C., Castelli-Gattinara G., Vigano A., El Mehabresh M.I., Newell M.L. HIV and HCV progression in parenterally coinfected children. Curr HIV Res 2009, 7:346-353.
153. Gisselquist D., Perrin L., Minkin S.F. Parallel and overlapping HIV and bloodborne hepatitis epidemics in Africa. Int J STD AIDS 2004, 15:145-152.
154. Mphahlele M.J., Lukhwareni A., Burnett R.J., Moropeng L.M., Ngobeni J.M. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006, 35:14-20.
155. Rouet F., Chaix M.L., Kpozehouen A., Inwoley A., Anaky M.F., Fassinou P., et al. Relationship of CD4+ T-cell counts and plasma HIV-1 RNA levels with serological HBeAg/anti-HBe patterns obtained in West-African HBV-HIV-1-co-infected children. J Trop Pediatr 2009, 55:409-412.
156. Shimelis T., Torben W., Medhin G., Tebeje M., Andualm A., Demessie F., et al. Hepatitis B virus infection among people attending the voluntary counselling and testing centre and anti-retroviral therapy clinic of St Paul's General Specialised Hospital, Addis Ababa, Ethiopia. Sex Transm Infect 2008, 84:37-41.
157. Klenerman P., Kim A. HCV-HIV coinfection: simple messages from a complex disease. PLoS Med 2007, 4:e240.
158. Amin J., Dore G.J., O'Connell D.L., Bartlett M., Tracey E., Kaldor J.M., et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol 2006, 45:197-203.
159. Puoti M., Torti C., Bruno R., Filice G., Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006, 44:S65-S70.
160. Ilboudo D., Karou D., Nadembega W.M., Savadogo A., Djeneba O., Pignatelli S., et al. Prevalence of human herpes virus-8 and hepatitis B virus among HIV seropositive pregnant women enrolled in the Mother-to-Child HIV Transmission Prevention Program at Saint Camille Medical Centre in Burkina Faso. Pak J Biol Sci 2007, 10:2831-2837.